01—Abstract
Summary
Summary of the 8-K filed May 28, 2024. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. filed this Form 8-K on May 28, 2024 under Item 7.01 (Regulation FD Disclosure) to announce that members of its executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4, 2024 at 2:00 p.m.
(CT). The filing is informational in nature and does not report financial results, transactions, or changes in management or guidance. The company describes itself in the attached press release (Exhibit 99.1) as a global leader of innovative and comprehensive laboratory services serving doctors, hospitals, pharmaceutical companies, researchers and patients.
The press release states the company has more than 67,000 employees, serves clients in approximately 100 countries, supported 84%a of the new drugs and therapeutic products approved by the FDA in 2023, and performed more than 600 million tests for patients worldwide. For investors, the filing offers an opportunity to hear from management at a investor conference, but it contains no new financial figures, guidance, or material corporate events. Investors seeking financial performance details would need to consult the company's periodic reports and earnings materials.
02—Key points
Key Highlights
- Labcorp will present at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4, 2024 at 2:00 p.m. (CT).
- Executive management team members will participate in the presentation, per Item 7.01 Regulation FD Disclosure.
- The company states it has more than 67,000 employees and serves clients in approximately 100 countries.
- Labcorp states it supported 84% of new drugs and therapeutic products approved by the FDA in 2023.
- The company states it performed more than 600 million tests for patients around the world.
- The filing contains no reported financial results, guidance, or transactions.
- Common stock (par value $0.10) trades on the New York Stock Exchange under the symbol LH.
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The filing furnishes under Item 7.01 (Regulation FD Disclosure) a press release announcing that Labcorp executive management will present at the 44th Annual William Blair Growth Stock Conference on June 4, 2024 at 2:00 p.m. (CT).
When and where is the conference presentation?
The presentation is scheduled for Tuesday, June 4 at 2:00 p.m. (CT) at the 44th Annual William Blair Growth Stock Conference.
Does this filing report financial results or guidance?
No. The filing addresses only the conference participation announcement and does not include financial results, earnings guidance, or other financial figures.
What does Labcorp say about its business scope?
The press release describes Labcorp as a global leader of laboratory services with more than 67,000 employees, clients in approximately 100 countries, support for 84% of FDA-approved new drugs and therapeutic products in 2023, and more than 600 million tests performed for patients.
Who are the investor relations contacts?
The press release lists Christin O'Donnell as the investor contact at 336-436-5076 and [email protected].
04—Continue